<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<atom:link href="http://wiley-blackwell.jellycast.com/podcast/feed/25" rel="self" type="application/rss+xml" />
 <title>Peter Sandercock and IST-3</title>
 <link>http://www.jellycast.com</link>
 <description>Acute ischemic stroke is a major public health burden and globally a common cause of death and disability</description>
 <language>en-PI</language>
 <copyright>http://creativecommons.org/licenses/by/2.0/</copyright>
 <generator>JellyCast http://www.jellycast.com</generator>
 <managingEditor>fiaria@wiley.com (wiley-blackwell)</managingEditor>
<category>Science</category>
 <pubDate>Tue, 10 Aug 2010 09:04:44 +0100</pubDate>
 <lastBuildDate>Tue, 17 Aug 2010 14:21:57 +0100</lastBuildDate>

<image>
 <url>https://wiley-blackwell.jellycast.com/files/123235932%5B1%5D_12.JPG</url>
 <title>Peter Sandercock and IST-3</title>
 <link>http://www.jellycast.com</link>
<width>144</width>
<height>144</height>
 <description>Acute ischemic stroke is a major public health burden and globally a common cause of death and disability</description>
 </image>

 <itunes:author>International Journal of Stroke</itunes:author>
 <itunes:image href="https://wiley-blackwell.jellycast.com/files/123235932%5B1%5D_11.JPG" />
 <itunes:owner>
 <itunes:name>wiley-blackwell</itunes:name>
 <itunes:email>fiaria@wiley.com</itunes:email>
 </itunes:owner>
 <itunes:keywords>podcast</itunes:keywords>
 <itunes:explicit>No</itunes:explicit>
 <itunes:block>No</itunes:block>
 <itunes:subtitle>Acute ischemic stroke is a major public health burden and globally a common cause of death and disability</itunes:subtitle>
 <itunes:summary>Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.</itunes:summary>
 <itunes:category text='Science' />

<item>
 <title>Peter Sandercock and IST-3</title>
 <link>https://wiley-blackwell.jellycast.com/node/26</link>
 <description>Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.</description>
 <enclosure url="https://wiley-blackwell.jellycast.com/files/audio/Peter%20Sandercock%20IST%20.mp3" length="6196580" type="audio/mpeg" />
 <pubDate>Tue, 17 Aug 2010 14:23:03 +0100</pubDate>
 <content:encoded>Content</content:encoded>
 <comments>https://wiley-blackwell.jellycast.com/node/26</comments>
 <dc:creator>jellycast</dc:creator>
 <guid>https://wiley-blackwell.jellycast.com/node/26</guid>
 <itunes:explicit>No</itunes:explicit>
 <itunes:keywords>Podcast</itunes:keywords>
 <itunes:duration>00:12:54</itunes:duration>
 <itunes:image href="https://wiley-blackwell.jellycast.com/files/123235932%5B1%5D_12.JPG" />
</item>
</channel>
</rss>
